icon-    folder.gif   Conference Reports for NATAP  
 
  EASL
43rd Annual Meeting of the European Association For The Study Of The Liver
Milan, Italy
April 23-27, 2008
Back grey_arrow_rt.gif
 
 
 
SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY
 
 
  Reported by Jules Levin
43rd EASL
April 23-27, 2008-05-01Milan, Italy
 

G-1.gif

Peter Ferenci, Thomas M. Scherzer,
Harald Hofer, Katharina Staufer, Petra Munda
 
Internal Medicine 3
Medical University of Vienna
AUSTRIA
 
This study was supported by an unrestricted research grant by ROCHE Austria, Silibinin was provided by ROTTAPHARM-MADAUS free of charge
 
AUTHOR SUMMARY
 
iv. silibinin has potent antiviral activity against HCV
 
This effect is dose dependent, and independent of peginterferon/ribavirin
 
iv. silibinin was well tolerated
 
oral administration of silymarin was ineffective
 
AUTHOR CONCLUSIONS
 
iv. silibinin may be useful for treatment of nonresponders to peginterferon/ribavirin
 
the optimal dose and duration of silibinin therapy remains to be studied
 
Studies of the pharmacokinetics of silibinin are mandatory
 
The mechanism of action is unknown
 

Silid-2.gif

Silymarin
 
Silymarin is a potentially useful drug for treatment of liver diseases
 
-- Clinical studies not conclusive
 
--mode of action
antioxidant/free radical scavenger
antifibrotic
Hepatoprotective (Amanita phalloides)
 
Study 1
 
Decrease of oxidative stress by high dose silibinin improved efficacy of interferon?
 
Pedigreed nonresponders
 
Full dose peginterferon/RBV for at least 12 weeks
 
-- < 2log drop week 12
 
-- HCV-RNA pos.at week 24
 

PROTO-3.gif

HCV-4.gif

Loge-5.gif

protto-6.gif

Drop-7.gif

Mg-8.gif

ALT-9.gif

Jutm-10.gif